AstraZeneca and J&J Resume Late-Stage Trials: How It Shakes Up the Coronavirus Vaccine Race

For a while, the U.S. late-stage clinical trials of coronavirus vaccine candidates developed by AstraZeneca (NYSE: AZN) and Johnson & Johnson (NYSE: JNJ) were in limbo. On Friday, AstraZeneca announced that the U.S. Food and Drug Administration authorized the resumption of the late-stage study for coronavirus vaccine candidate AZD1222. The same day, J&J announced that it also was preparing to resume the U.S. late-stage study of its experimental COVID-19 vaccine, JNJ-78436735.